Search Results - "Martínez‐Sáez, Olga"

Frequency and spectrum of PIK3CA somatic mutations in breast cancer by Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix

“…The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced…”
Get full text

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, Prat, Aleix

“…Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of…”
Get full text

Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts by Weiss, Anna, Martínez‐Sáez, Olga, Waks, Adrienne G., Laws, Alison, McGrath, Monica, Tarantino, Paolo, Portnow, Leah, Winer, Eric, Rey, María, Tapia, Marta, Prat, Aleix, Partridge, Ann H., Tolaney, Sara M., Cejalvo, Juan M., Mittendorf, Elizabeth A., King, Tari A.

“…Background The optimal treatment strategy for patients with small human epidermal growth factor receptor 2 (HER2)‐positive tumors is based on nodal status. The…”
Get full text

Gene expression profiles of breast cancer metastasis according to organ site by Brasó‐Maristany, Fara, Paré, Laia, Chic, Nuria, Martínez‐Sáez, Olga, Pascual, Tomás, Mallafré‐Larrosa, Meritxell, Schettini, Francesco, González‐Farré, Blanca, Sanfeliu, Esther, Martínez, Débora, Galván, Patricia, Barnadas, Esther, Salinas, Belinda, Tolosa, Pablo, Ciruelos, Eva, Carcelero, Esther, Guillén, Cecilia, Adamo, Barbara, Moreno, Reinaldo, Vidal, Maria, Muñoz, Montserrat, Prat, Aleix

“…In advanced breast cancer, biomarker identification and patient selection using a metastatic tumor biopsy is becoming more necessary. However, the biology of…”
Get full text

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer by Prat, Aleix, Brasó-Maristany, Fara, Martínez-Sáez, Olga, Sanfeliu, Esther, Xia, Youli, Bellet, Meritxell, Galván, Patricia, Martínez, Débora, Pascual, Tomás, Marín-Aguilera, Mercedes, Rodríguez, Anna, Chic, Nuria, Adamo, Barbara, Paré, Laia, Vidal, Maria, Margelí, Mireia, Ballana, Ester, Gómez-Rey, Marina, Oliveira, Mafalda, Felip, Eudald, Matito, Judit, Sánchez-Bayona, Rodrigo, Suñol, Anna, Saura, Cristina, Ciruelos, Eva, Tolosa, Pablo, Muñoz, Montserrat, González-Farré, Blanca, Villagrasa, Patricia, Parker, Joel S., Perou, Charles M., Vivancos, Ana

“…Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with…”
Get full text

Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors by Molina‐Cerrillo, Javier, Alonso‐Gordoa, Teresa, Martínez‐Sáez, Olga, Grande, Enrique

“…The carcinoid syndrome represents a set of signs and symptoms associated with neuroendocrine tumors (NETs) that occur primarily when metastases are developed…”
Get full text

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response by Brasó-Maristany, Fara, Ferrero-Cafiero, Juan Manuel, Falato, Claudette, Martínez-Sáez, Olga, Cejalvo, Juan Miguel, Margelí, Mireia, Tolosa, Pablo, Salvador-Bofill, Francisco Javier, Cruz, Josefina, González-Farré, Blanca, Sanfeliu, Esther, Òdena, Andreu, Serra, Violeta, Pardo, Francisco, Luna Barrera, Ana María, Arumi, Miriam, Guerra, Juan Antonio, Villacampa, Guillermo, Sánchez-Bayona, Rodrigo, Ciruelos, Eva, Espinosa-Bravo, Martín, Izarzugaza, Yann, Galván, Patricia, Matito, Judith, Pernas, Sonia, Vidal, Maria, Santhanagopal, Anu, Sellami, Dalila, Esker, Stephen, Fan, Pang-Dian, Suto, Fumitaka, Vivancos, Ana, Pascual, Tomás, Prat, Aleix, Oliveira, Mafalda

“…Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3 /HER3 levels. This…”
Get full text

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer by Lorman-Carbó, Natàlia, Martínez-Sáez, Olga, Fernandez-Martinez, Aranzazu, Galván, Patricia, Chic, Nuria, Garcia-Fructuoso, Isabel, Rodríguez, Adela, Gómez-Bravo, Raquel, Schettini, Francesco, Blasco, Paula, Castillo, Oleguer, González-Farré, Blanca, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Perou, Charles M., Malumbres, Marcos, Gavilá, Joaquín, Pascual, Tomás, Prat, Aleix, Brasó-Maristany, Fara

“…This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase…”
Get full text

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer by Pascual, Tomás, Oliveira, Mafalda, Ciruelos, Eva, Bellet Ezquerra, Meritxell, Saura, Cristina, Gavilá, Joaquin, Pernas, Sonia, Muñoz, Montserrat, Vidal, Maria J, Margelí Vila, Mireia, Cejalvo, Juan M, González-Farré, Blanca, Espinosa-Bravo, Martin, Cruz, Josefina, Salvador-Bofill, Francisco Javier, Guerra, Juan Antonio, Luna Barrera, Ana María, Arumi de Dios, Miriam, Esker, Stephen, Fan, Pang-Dian, Martínez-Sáez, Olga, Villacampa, Guillermo, Paré, Laia, Ferrero-Cafiero, Juan M, Villagrasa, Patricia, Prat, Aleix

“…Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently,…”
Get full text

The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide by Serrano Domingo, Juan José, Alonso Gordoa, Teresa, Lorca Álvaro, Javier, Molina-Cerrillo, Javier, Barquín García, Arantzazu, Martínez Sáez, Olga, Burgos Revilla, Javier, Carrato, Alfredo, Álvarez Rodríguez, Sara

“…Introduction: Androgenic deprivation therapies have been linked to the development of metabolic syndrome (MS) and cardiovascular diseases, which may lead to a…”
Get full text

Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer by Tarantino, Paolo, Leone, Julieta, Vallejo, Carlos T., Freedman, Rachel A., Waks, Adrienne G., Martínez-Sáez, Olga, Garrido-Castro, Ana, Lynce, Filipa, Tayob, Nabihah, Lin, Nancy U., Tolaney, Sara M., Leone, Jose P.

“…To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients…”
Get full text

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy by Chic, Nuria, Schettini, Francesco, Brasó-Maristany, Fara, Sanfeliu, Esther, Adamo, Barbara, Vidal, Maria, Martínez, Débora, Galván, Patricia, González-Farré, Blanca, Cortés, Javier, Gavilá, Joaquín, Saura, Cristina, Oliveira, Mafalda, Pernas, Sònia, Martínez-Sáez, Olga, Soberino, Jesús, Ciruelos, Eva, Carey, Lisa A., Muñoz, Montserrat, Perou, Charles M., Pascual, Tomás, Bellet, Meritxell, Prat, Aleix

“…Chemotherapy efficacy in early-stage hormone receptor-positive (HR+) breast cancer (BC) according to menopausal status needs a biological explanation. We…”
Get full text

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy by Martínez-Sáez, Olga, Pascual, Tomás, Brasó-Maristany, Fara, Chic, Nuria, González-Farré, Blanca, Sanfeliu, Esther, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Anna Belén, Schettini, Francesco, Conte, Benedetta, Vidal, Maria, Adamo, Barbara, Martínez, Antoni, Muñoz, Montserrat, Moreno, Reinaldo, Villagrasa, Patricia, Salvador, Fernando, Ciruelos, Eva M., Faull, Iris, Odegaard, Justin I., Prat, Aleix

“…Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET);…”
Get full text

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 by Brasó-Maristany, Fara, Griguolo, Gaia, Chic, Nuria, Pascual, Tomás, Paré, Laia, Maues, Julia, Galván, Patricia, Dieci, Maria Vittoria, Miglietta, Federica, Giarratano, Tommaso, Martínez-Sáez, Olga, Marín-Aguilera, Mercedes, Schettini, Francesco, Conte, Benedetta, Angelats, Laura, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Sanfeliu, Esther, González, Blanca, Vivancos, Ana, Villagrasa, Patricia, Parker, Joel S, Perou, Charles M, Conte, PierFranco, Prat, Aleix, Guarneri, Valentina

“…Abstract In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab…”
Get full text

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab by Waks, Adrienne G, Ogayo, Esther R, Paré, Laia, Marín-Aguilera, Mercedes, Brasó-Maristany, Fara, Galván, Patricia, Castillo, Oleguer, Martínez-Sáez, Olga, Vivancos, Ana, Villagrasa, Patricia, Villacampa, Guillermo, Tarantino, Paolo, Desai, Neelam, Guerriero, Jennifer, Metzger, Otto, Tung, Nadine M, Krop, Ian E, Parker, Joel S, Perou, Charles M, Prat, Aleix, Winer, Eric P, Tolaney, Sara M, Mittendorf, Elizabeth A

“…Patients with early-stage ERBB2 (formerly HER2)-positive breast cancer (ERBB2+ BC) who experience a pathologic complete response (pCR) after receiving…”
Get more information

A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies by Conte, Benedetta, Brasó-Maristany, Fara, Hernández, Adela Rodríguez, Pascual, Tomás, Villacampa, Guillermo, Schettini, Francesco, Vidal Losada, Maria J., Seguí, Elia, Angelats, Laura, Garcia-Fructuoso, Isabel, Gómez-Bravo, Raquel, Lorman-Carbó, Natàlia, Paré, Laia, Marín-Aguilera, Mercedes, Martínez-Sáez, Olga, Adamo, Barbara, Sanfeliu, Esther, Fratini, Beatrice, Falato, Claudette, Chic, Núria, Vivancos, Ana, Villagrasa, Patricia, Staaf, Johan, Parker, Joel S., Perou, Charles M., Prat, Aleix

“…Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial…”
Get full text

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, Prat, Aleix

Get full text

Current and Future Management of HER2-Positive Metastatic Breast Cancer by Martínez-Sáez, Olga, Prat, Aleix

“…Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in approximately 20% of breast cancers, conferring an aggressive tumor…”
Get more information

Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): A population-based study by Tarantino, Paolo, Leone, Julieta, Vallejo, Carlos Teodoro, Freedman, Rachel A., Waks, Adrienne Gropper, Martínez-Sáez, Olga, Garrido-Castro, Ana Christina, Lynce, Filipa, Tayob, Nabihah, Lin, Nancy U., Tolaney, Sara M., Leone, Jose Pablo

“…510 Background: Outcomes for patients with stage IA TNBC in the modern era remain poorly characterized, and the benefit and utilization of adjuvant…”
Get full text

Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder by Carrillo, Pilar, Gorría, Teresa, Santana, Daniel, Sepulveda, Maria, Aldecoa, Iban, Gonzalez-Farré, Blanca, Sanfeliu, Esther, Mension, Eduard, Cebrecos, Isaac, Martínez-Saez, Olga, Alonso, Imma, Saiz, Albert

“…Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory central nervous system disorder that preferentially affects the optic nerve and…”
Get full text